192 related articles for article (PubMed ID: 35746461)
1. Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study.
Assawasaksakul T; Lertussavavivat T; Sathitratanacheewin S; Oudomying N; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Avihingsanon Y; Assawasaksakul N; Buranapraditkun S; Kittanamongkolchai W
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746461
[TBL] [Abstract][Full Text] [Related]
2. Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.
Szebeni GJ; Gémes N; Honfi D; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Szekanecz Z; Puskás LG; Toldi G; Balog A
Front Immunol; 2022; 13():846248. PubMed ID: 35432314
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
Wanlapakorn N; Suntronwong N; Phowatthanasathian H; Yorsaeng R; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Klinfueng S; Sudhinaraset N; Poovorawan Y
Vaccine; 2022 May; 40(23):3203-3209. PubMed ID: 35465981
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations.
Sudjaritruk T; Mueangmo O; Saheng J; Winichakoon P; Salee P; Wongjak W; Chaito T; Praparattanapan J; Nuket K; Solai N; Wipasa J; Chawansuntati K; Chaiwarith R
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992147
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
[TBL] [Abstract][Full Text] [Related]
6. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
7. Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.
Szabó E; Modok S; Rónaszéki B; Faragó A; Gémes N; Nagy LI; Hackler L; Farkas K; Neuperger P; Balog JÁ; Balog A; Puskás LG; Szebeni GJ
Front Med (Lausanne); 2023; 10():1176168. PubMed ID: 37529238
[TBL] [Abstract][Full Text] [Related]
8. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
Suntronwong N; Kanokudom S; Auphimai C; Assawakosri S; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Puenpa J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
J Med Virol; 2022 Dec; 94(12):5713-5722. PubMed ID: 35924475
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.
Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Kittanamongkolchai W
RMD Open; 2021 Dec; 7(3):. PubMed ID: 34862313
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis.
Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Avihingsanon Y; Assawasaksakul N; Kittanamongkolchai W
Lupus Sci Med; 2022 Jul; 9(1):. PubMed ID: 35902168
[TBL] [Abstract][Full Text] [Related]
11. Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
Expert Rev Vaccines; 2022 Dec; 21(12):1873-1881. PubMed ID: 35792752
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus.
Piyaphanee N; Charuvanij S; Thepveera S; Toh ZQ; Licciardi PV; Pattaragarn A; Wongprompitak P; Boonnak K; Pheerapanyawaranun C; Chokephaibulkit K
Lupus; 2024 Apr; 33(5):450-461. PubMed ID: 38335115
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.
Colmegna I; Valerio V; Amiable N; Useche M; Rampakakis E; Flamand L; Rollet-Labelle E; Bessette L; Fitzcharles MA; Hazel E; McCormack D; Michou L; Panopalis P; Langlois MA; Bernatsky S; Fortin PR
RMD Open; 2023 Nov; 9(4):. PubMed ID: 38030231
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
Cohen G; Jungsomsri P; Sangwongwanich J; Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
Hum Vaccin Immunother; 2022 Nov; 18(5):2052525. PubMed ID: 35323079
[TBL] [Abstract][Full Text] [Related]
18. Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
Zhu F; Jin P; Zhu T; Wang W; Ye H; Pan H; Hou L; Li J; Wang X; Wu S; Wang Y; Gou J; Huang H; Wu H; Wang X; Chen W
Clin Infect Dis; 2022 Aug; 75(1):e783-e791. PubMed ID: 34551104
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
Yorsaeng R; Suntronwong N; Phowatthanasathian H; Assawakosri S; Kanokudom S; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
Vaccine; 2022 Jan; 40(3):524-530. PubMed ID: 34893344
[TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
